Overview

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Status:
Unknown status
Trial end date:
2019-10-30
Target enrollment:
Participant gender:
Summary
This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.